Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100


MYC-induced epigenetic activation of GATA4 in lung adenocarcinoma.

Castro IC, Breiling A, Luetkenhaus K, Ceteci F, Hausmann S, Kress S, Lyko F, Rudel T, Rapp UR.

Mol Cancer Res. 2013 Feb;11(2):161-72. doi: 10.1158/1541-7786.MCR-12-0414-T. Epub 2012 Dec 13.


Epigenetic regulation of GATA4 expression by histone modification in AFP-producing gastric adenocarcinoma.

Yamamura N, Kishimoto T.

Exp Mol Pathol. 2012 Aug;93(1):35-9. doi: 10.1016/j.yexmp.2012.03.012. Epub 2012 Mar 24.


Cigarette smoke mediates epigenetic repression of miR-487b during pulmonary carcinogenesis.

Xi S, Xu H, Shan J, Tao Y, Hong JA, Inchauste S, Zhang M, Kunst TF, Mercedes L, Schrump DS.

J Clin Invest. 2013 Mar;123(3):1241-61. doi: 10.1172/JCI61271. Epub 2013 Feb 15.


Activated Notch1 induces lung adenomas in mice and cooperates with Myc in the generation of lung adenocarcinoma.

Allen TD, Rodriguez EM, Jones KD, Bishop JM.

Cancer Res. 2011 Sep 15;71(18):6010-8. doi: 10.1158/0008-5472.CAN-11-0595. Epub 2011 Jul 29.


Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression.

Selamat SA, Chung BS, Girard L, Zhang W, Zhang Y, Campan M, Siegmund KD, Koss MN, Hagen JA, Lam WL, Lam S, Gazdar AF, Laird-Offringa IA.

Genome Res. 2012 Jul;22(7):1197-211. doi: 10.1101/gr.132662.111. Epub 2012 May 21.


Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas.

Bouillez A, Rajabi H, Pitroda S, Jin C, Alam M, Kharbanda A, Tagde A, Wong KK, Kufe D.

Cancer Res. 2016 Mar 15;76(6):1538-48. doi: 10.1158/0008-5472.CAN-15-1804. Epub 2016 Feb 1.


Hypermethylation of the GATA genes in lung cancer.

Guo M, Akiyama Y, House MG, Hooker CM, Heath E, Gabrielson E, Yang SC, Han Y, Baylin SB, Herman JG, Brock MV.

Clin Cancer Res. 2004 Dec 1;10(23):7917-24.


Genome-wide DNA methylation analysis of lung carcinoma reveals one neuroendocrine and four adenocarcinoma epitypes associated with patient outcome.

Karlsson A, Jönsson M, Lauss M, Brunnström H, Jönsson P, Borg Å, Jönsson G, Ringnér M, Planck M, Staaf J.

Clin Cancer Res. 2014 Dec 1;20(23):6127-40. doi: 10.1158/1078-0432.CCR-14-1087. Epub 2014 Oct 2.


Decoding c-Myc networks of cell cycle and apoptosis regulated genes in a transgenic mouse model of papillary lung adenocarcinomas.

Ciribilli Y, Singh P, Spanel R, Inga A, Borlak J.

Oncotarget. 2015 Oct 13;6(31):31569-92. doi: 10.18632/oncotarget.5035.


EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF.

Chou YT, Lin HH, Lien YC, Wang YH, Hong CF, Kao YR, Lin SC, Chang YC, Lin SY, Chen SJ, Chen HC, Yeh SD, Wu CW.

Cancer Res. 2010 Nov 1;70(21):8822-31. doi: 10.1158/0008-5472.CAN-10-0638. Epub 2010 Oct 26.


Different pattern of expression of cellular oncogenes in human non-small-cell lung cancer cell lines.

Kiefer PE, Wegmann B, Bacher M, Erbil C, Heidtmann H, Havemann K.

J Cancer Res Clin Oncol. 1990;116(1):29-37.


Ampelopsin induces apoptosis by regulating multiple c-Myc/S-phase kinase-associated protein 2/F-box and WD repeat-containing protein 7/histone deacetylase 2 pathways in human lung adenocarcinoma cells.

Chen XM, Xie XB, Zhao Q, Wang F, Bai Y, Yin JQ, Jiang H, Xie XL, Jia Q, Huang G.

Mol Med Rep. 2015 Jan;11(1):105-12. doi: 10.3892/mmr.2014.2733. Epub 2014 Oct 21.


ROS1 receptor tyrosine kinase, a druggable target, is frequently overexpressed in non-small cell lung carcinomas via genetic and epigenetic mechanisms.

Lee HJ, Seol HS, Kim JY, Chun SM, Suh YA, Park YS, Kim SW, Choi CM, Park SI, Kim DK, Kim YH, Jang SJ.

Ann Surg Oncol. 2013 Jan;20(1):200-8. doi: 10.1245/s10434-012-2553-6. Epub 2012 Aug 23.


Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers.

Kaira K, Sunaga N, Tomizawa Y, Yanagitani N, Ishizuka T, Saito R, Nakajima T, Mori M.

Int J Oncol. 2007 Jul;31(1):169-73.


Genetic and epigenetic analysis of erbB signaling pathway genes in lung cancer.

Hoque MO, Brait M, Rosenbaum E, Poeta ML, Pal P, Begum S, Dasgupta S, Carvalho AL, Ahrendt SA, Westra WH, Sidransky D.

J Thorac Oncol. 2010 Dec;5(12):1887-93. doi: 10.1097/JTO.0b013e3181f77a53. Erratum in: J Thorac Oncol. 2011 Feb;6(2):409.


Overexpression of Long Non-Coding RNA ZXF2 Promotes Lung Adenocarcinoma Progression Through c-Myc Pathway.

Yang ZT, Li Z, Wang XG, Tan T, Yi F, Zhu H, Zhao JP, Zhou XF.

Cell Physiol Biochem. 2015;35(6):2360-70. doi: 10.1159/000374038. Epub 2015 Apr 15.


Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins.

Lockwood WW, Zejnullahu K, Bradner JE, Varmus H.

Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19408-13. doi: 10.1073/pnas.1216363109. Epub 2012 Nov 5.


Inhibition of Myc effectively targets KRAS mutation-positive lung cancer expressing high levels of Myc.

Fukazawa T, Maeda Y, Matsuoka J, Yamatsuji T, Shigemitsu K, Morita I, Faiola F, Durbin ML, Soucek L, Naomoto Y.

Anticancer Res. 2010 Oct;30(10):4193-200.


Synergistic induction of the Fas (CD95) ligand promoter by Max and NFkappaB in human non-small lung cancer cells.

Wiener Z, Ontsouka EC, Jakob S, Torgler R, Falus A, Mueller C, Brunner T.

Exp Cell Res. 2004 Sep 10;299(1):227-35.


Supplemental Content

Support Center